Latest / PETRI DISH PERSPECTIVES
Episode 69: Summit Therapeutics
Send us Fan Mail
In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely watched oncology companies in the world. At the center of the story is ivonescimab, a next-generation bispecific antibody targeting both PD-1 and VEGF and a drug that could potentially challenge Merck’s blockbuster Keytruda.
We’ll dive into Summit’s origins, the company’s dramatic pivot, the story behind its partnership with China’s Akeso, and the science behind why combining immune…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.